Research and Practice in Thrombosis and Haemostasis最新文献

{"title":"Exploration of the plasma proteomic profile of patients at risk of thromboembolic events","authors":"Eva R. Smit ,&nbsp;Iris C. Kreft ,&nbsp;Eleonora Camilleri ,&nbsp;J. Louise I. Burggraaf-van Delft ,&nbsp;Nienke van Rein ,&nbsp;Bart J.M. van Vlijmen ,&nbsp;Anne-Marije Hulshof ,&nbsp;Bas C.T. van Bussel ,&nbsp;Frank van Rosmalen ,&nbsp;Carmen van der Zwaan ,&nbsp;Tom van de Berg ,&nbsp;Yvonne Henskens ,&nbsp;Hugo ten Cate ,&nbsp;Jonathan M. Coutinho ,&nbsp;Marieke J.H.A. Kruip ,&nbsp;Jeroen J.C. Eikenboom ,&nbsp;Arie J. Hoogendijk ,&nbsp;Suzanne C. Cannegieter ,&nbsp;Maartje van den Biggelaar ,&nbsp;Mihaela Zlei","doi":"10.1016/j.rpth.2025.102713","DOIUrl":"10.1016/j.rpth.2025.102713","url":null,"abstract":"<div><h3>Background</h3><div>The elevated health burden of thromboembolic events necessitates development of blood-based risk monitoring tools.</div></div><div><h3>Objectives</h3><div>We explored the potential of mass spectrometry–based plasma proteomics to provide insights into underlying plasma protein signatures associated with treatment and occurrence of thromboembolic events.</div></div><div><h3>Methods</h3><div>Utilizing a high-throughput, data-independent acquisition, discovery-based proteomics workflow, we analyzed 434 plasma proteomes from different groups of individuals with elevated risk of thromboembolic events, including individuals I) on vitamin K antagonists (VKAs; <em>n</em> = 130), II) with a prior venous thromboembolism (<em>n</em> = 10), III) with acute cerebral venous sinus thrombosis (<em>n</em> = 10, and IV) with SARS-CoV-2 infection (<em>n</em> = 67). Plasma protein levels measured with mass spectrometry were correlated with international normalized ratio and conventional clinical laboratory measurements. Plasma profile differences between different groups were assessed using principal component analysis, moderated <em>t</em>-test, and clustering analysis.</div></div><div><h3>Results</h3><div>Plasma protein levels were in agreement with conventional clinical laboratory parameters, including albumin and fibrinogen. Levels of vitamin K–dependent proteins inversely correlated with international normalized ratio. In the individual studies, we found decreased levels of vitamin K–dependent coagulation proteins in patients on VKAs, alterations in inflammatory signatures among CVST patients and a distinctive signature indicative of SARS-CoV-2 infection. However, no protein signature associated with a thromboembolic event could be identified neither in individual nor combined studies.</div></div><div><h3>Conclusion</h3><div>Although VKA treatment–specific and disease-specific signatures were captured, our study highlights that the challenges of discovering biomarkers in patients at risk of thromboembolic events lie in the heterogeneity of individual plasma profiles in relation to treatment and etiology.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102713"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extravascular factor IX after gene therapy in hemophilia B, does it matter?","authors":"Quentin Van Thillo ,&nbsp;Cédric Hermans","doi":"10.1016/j.rpth.2025.102723","DOIUrl":"10.1016/j.rpth.2025.102723","url":null,"abstract":"<div><div>Gene therapy will very likely change the treatment paradigm of hemophilia B in the coming years. For the majority of patients, adjunctive exogenous factor (F)IX clotting factor concentrate will continue to be needed in case of surgery or bleeding. However, there is insufficient evidence on the optimal FIX product to be used in these circumstances, given the differences in body distribution between the currently available products. Unknown factors include the behavior of FIX Padua in the extravascular space and its contribution to hemostasis. Other issues are the potential importance of the presence of cross-reactive material and the discrepancies between different assays in measuring FIX activity. In conclusion, even after gene therapy, the differences between different FIX products remain relevant for optimal bleeding and perioperative management. Thus, real-world data on the use of exogenous FIX after gene therapy are needed to determine the preferred exogenous FIX concentrate.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102723"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise capacity, dyspnea, and quality of life 6 months after exercise-based rehabilitation in patients with persistent dyspnea following pulmonary embolism","authors":"Stacey Haukeland-Parker ,&nbsp;Øyvind Jervan ,&nbsp;Waleed Ghanima ,&nbsp;Martijn A. Spruit ,&nbsp;René Holst ,&nbsp;Jostein Gleditsch ,&nbsp;Mazdak Tavoly ,&nbsp;Knut Stavem ,&nbsp;Kjetil Steine ,&nbsp;Dan Atar ,&nbsp;Anders Erik Astrup Dahm ,&nbsp;Frederikus A. Klok ,&nbsp;Hege Hølmo Johannessen","doi":"10.1016/j.rpth.2025.102736","DOIUrl":"10.1016/j.rpth.2025.102736","url":null,"abstract":"<div><h3>Background</h3><div>Exercise is safe and effective in the short-term following pulmonary embolism. To date, little is known about the long-term effects.</div></div><div><h3>Objectives</h3><div>The aim of the study was to investigate whether the effects of exercise-based rehabilitation are maintained 6 months after completion in patients with persistent dyspnea following pulmonary embolism when compared with usual care.</div></div><div><h3>Methods</h3><div>A 2-center, randomized controlled trial compared 8 weeks of exercise-based rehabilitation with usual care. Patients were reassessed postintervention and 6 months later. Exercise capacity was measured with the incremental shuttle walk test (ISWT). Dyspnea was assessed with the Shortness of Breath Questionnaire, and health-related quality of life was assessed with disease-specific (Pulmonary Embolism Quality of Life Questionnaire) and generic questionnaires.</div></div><div><h3>Results</h3><div>In total, 159 of 211 randomized patients attended follow-up 6 months postintervention. The significant improvement on the ISWT in the rehabilitation group was maintained at the 6-month follow-up (96 m; SE: 15 m; 95% CI: 66, 127). There were no changes on the ISWT in the control group at either time point. From postintervention to 6×-month follow-up, the rehabilitation group had further improvements in dyspnea compared with the control group (−3 points; SE: 1.4; 95% CI: −6, −1; <em>P</em> = .02). Health-related quality of life improved in both groups although superior improvements were seen in the rehabilitation group.</div></div><div><h3>Conclusion</h3><div>The improvement in exercise capacity after 8 weeks of exercise-based rehabilitation in patients with pulmonary embolism and persistent dyspnea was maintained at the 6-month follow-up, while no improvement was observed in the control group, highlighting the relevance of offering rehabilitation to these patients.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102736"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protofibril packing density of individual fibers alters fibrinolysis","authors":"Rebecca A. Risman ,&nbsp;Victoria Percoco ,&nbsp;Bradley Paynter ,&nbsp;Brittany E. Bannish ,&nbsp;Valerie Tutwiler","doi":"10.1016/j.rpth.2025.102708","DOIUrl":"10.1016/j.rpth.2025.102708","url":null,"abstract":"<div><h3>Background</h3><div>Many diseased conditions alter the fibrinogen and clotting activator concentrations, resulting in a unique network structure that may be resistant or susceptible to lysis. While much is known about the relationship between structure and lysis, previous studies overlooked confounding factors in the fibrin network structure that must be considered to develop targeted therapeutics.</div></div><div><h3>Objectives</h3><div>We aimed to determine how fiber diameter, network pore size, and protofibril packing density work together and individually to impact lysis.</div></div><div><h3>Methods</h3><div>We used turbidimetry to kinetically monitor clot formation, protofibril packing, and lysis of clots formed with the 2 activators. We characterized the unique clot structures during lysis using confocal and scanning electron microscopy. With our stochastic multiscale mathematical model of fibrinolysis, we varied the fibrin content per fiber to probe the role of protofibril packing density on a clot’s susceptibility to degradation.</div></div><div><h3>Results</h3><div>Plasma clots activated with tissue factor had denser fibrin networks with looser protofibril packing that were initially degraded faster than clots activated with thrombin, which had loose fibrin networks and dense protofibril packing. Modeling revealed that the fibrin content per fiber dictates individual fiber lysis time and the time it takes tissue-type plasminogen activator to travel between fibers.</div></div><div><h3>Conclusion</h3><div>The present work highlights the crucial role that protofibril packing density plays in fibrinolysis. Our results suggest a need to consider the effect a disease has on protofibril packing density to inform about clot resistance and the development for more personalized lytic agents.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102708"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of plasma-derived von Willebrand factor/factor VIII concentrate (wilate) prophylaxis in children and adolescents with von Willebrand disease – WIL-31 study post hoc analysis","authors":"Robert F. Sidonio Jr. ,&nbsp;Leonid Dubey ,&nbsp;Kateryna V. Vilchevska ,&nbsp;Adlette Inati ,&nbsp;Claudia Djambas Khayat","doi":"10.1016/j.rpth.2025.102719","DOIUrl":"10.1016/j.rpth.2025.102719","url":null,"abstract":"<div><h3>Background</h3><div>Prophylaxis with von Willebrand factor is recommended in people with severe von Willebrand disease (VWD), regardless of age. WIL-31, the only prospective study with an on-demand run-in study as an intraindividual comparator, demonstrated the efficacy and safety of prophylaxis with the plasma-derived von Willebrand factor/factor VIII concentrate wilate (Octapharma) in adults and children with VWD of all types. Prophylaxis is often considered in young children and adolescents with severe VWD and recurrent bleeding, although limited data support this strategy.</div></div><div><h3>Objectives</h3><div>To assess the efficacy of wilate prophylaxis in children (6-11 years) and adolescents (12-16 years) in WIL-31.</div></div><div><h3>Methods</h3><div>Patients received 20 to 40 IU/kg (Octapharma) wilate prophylaxis 2 to 3 times weekly for 12 months. Results were compared with prospective on-demand treatment.</div></div><div><h3>Results</h3><div>Mean total annualized bleeding rates (ABRs) during on-demand vs prophylaxis were 32.5 vs 3.7 in children (<em>n</em> = 9) and 28.9 vs 4.3 in adolescents (<em>n</em> = 6), representing reductions of 89% and 85%, respectively. All 34 bleeds in children, and 20/26 (77%) bleeds in adolescents were minor. Mean spontaneous ABRs during prophylaxis were 2.5 in children and 1.5 in adolescents. The most common bleeding site in both groups and across all VWD types was the nose. ABRs were reduced further during the second 6 months of prophylaxis vs the first 6 months. During the second 6 months, 78% of children and 67% of adolescents had zero spontaneous bleeds. No serious adverse events related to study treatment or thrombotic events were observed.</div></div><div><h3>Conclusion</h3><div>wilate prophylaxis was efficacious and well-tolerated in children and adolescents with all types of VWD.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102719"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibrinogen levels and bleeding risk in adult extracorporeal cardiopulmonary resuscitation: multicenter observational study subanalysis","authors":"Seiya Kanou ,&nbsp;Eiji Nakatani ,&nbsp;Tetsumei Urano ,&nbsp;Hatoko Sasaki ,&nbsp;Akihiko Inoue ,&nbsp;Toru Hifumi ,&nbsp;Tetsuya Sakamoto ,&nbsp;Yasuhiro Kuroda ,&nbsp;Yoshihiro Tanaka","doi":"10.1016/j.rpth.2025.102700","DOIUrl":"10.1016/j.rpth.2025.102700","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102700"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemophilia treatments and the paradox of choice","authors":"Mike Makris ,&nbsp;Brian O’Mahony","doi":"10.1016/j.rpth.2025.102726","DOIUrl":"10.1016/j.rpth.2025.102726","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102726"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2023 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for antiphospholipid syndrome: good for patients or good for papers?","authors":"Katrien M.J. Devreese","doi":"10.1016/j.rpth.2025.102735","DOIUrl":"10.1016/j.rpth.2025.102735","url":null,"abstract":"<div><div>The American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for antiphospholipid syndrome (APS) is a new set of robust criteria, including clinical and laboratory criteria, to enhance the identification of patients in clinical studies and laboratory research. Based on a scoring system, patients accruing at least 3 points in the clinical and laboratory domains fulfill the classification criteria for APS. They are meant to define homogeneous patient groups for research. They are not to be used in a clinical setting for diagnosis to identify every patient with APS, where it is essential to include those with an atypical clinical presentation and/or antiphospholipid antibodies laboratory test result. These criteria have provoked a debate among workers in the field. Without nuance, the classification criteria cannot be used for diagnosing APS and may be a potential pitfall for clinicians when no difference is made between “classification” and “diagnostic” criteria. Complementing the American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria with the recently available International Society on Thrombosis and Haemostasis guidance on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of APS has added value. It ensures rigorous research that leads to improvement of patient management and optimal clinical care in routine practice.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102735"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower early mortality and risk prediction improvement of obesity after acute pulmonary embolism: results from a multicenter cohort analysis with external validation","authors":"Romain Chopard ,&nbsp;Laurent Bertoletti ,&nbsp;Marc Badoz ,&nbsp;Nicolas Meneveau ,&nbsp;Fiona Ecarnot ,&nbsp;Luciano López Jiménez ,&nbsp;Olga Madridano ,&nbsp;José Antonio Díaz Peromingo ,&nbsp;Meritxell López De la Fuente ,&nbsp;Manuel Monreal ,&nbsp;Gregory Piazza ,&nbsp;RIETE Investigators","doi":"10.1016/j.rpth.2025.102718","DOIUrl":"10.1016/j.rpth.2025.102718","url":null,"abstract":"<div><h3>Background</h3><div>The relationship between obesity (defined as body mass index [BMI] ≥ 30 kg/m²) and mortality in venous thromboembolism remains controversial.</div></div><div><h3>Objectives</h3><div>We aimed to compare outcomes after pulmonary embolism (PE) between patients with obesity and nonobese, nonunderweight patients.</div></div><div><h3>Methods</h3><div>Using a multicenter registry of prospectively recorded individual patient data, we compared outcome rates using multivariable logistic or Cox regression for 30-day and 6-month outcomes respectively (etiologic analysis). We assessed the incremental value of adding BMI information on top of the 30-day European Society of Cardiology (ESC) prognostic algorithm (prognostic analysis).</div></div><div><h3>Results</h3><div>We included 2390 patients with BMI of ≥18.5 kg/m² (mean age, 66.9 ± 16.8 years; 1188 men [49.7%]); 686 patients [28.7%] were in the obese group. Mortality rates were significantly lower in patients with obesity than that in patients who were nonobese at 30 days (3.2% [95% CI, 2.0-4.8] vs 5.9% [95% CI, 4.8-7.1]), and 6 months (8.1% [95% CI, 6.2-10.4] vs 16.3% [95% CI, 14.6-18.1]). Rates of secondary nonfatal outcomes (including bleeding, recurrent venous thromboembolism, myocardial infarction, and stroke) did not differ between groups. The addition of the obesity information on top of the ESC prognostic model improved global model fit and discriminatory (Harrell C index from 0.636 to 0.657; <em>P</em> = .07) and calibration capacities (<em>P</em> (Hosmer–Lemeshow) = .02 vs .13), yielding significant reclassification (ie, 10.3%) based on the observed mortality rates with the ESC model as reference. Findings were confirmed in an external validation using 35,796 patients with PE from the RIETE registry.</div></div><div><h3>Conclusion</h3><div>We present evidence indicating lower early- and mid-term mortality after PE in patients classified as obese based on BMI, compared with nonobese, nonunderweight patients. BMI should likely be incorporated into algorithms or scoring systems for predicting early mortality following PE.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102718"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer","authors":"Nienke van Rein ,&nbsp;Gordon Chu ,&nbsp;Menno V. Huisman ,&nbsp;Lars Pedersen ,&nbsp;Henrik T. Sørensen ,&nbsp;Frederikus A. Klok ,&nbsp;Suzanne C. Cannegieter","doi":"10.1016/j.rpth.2025.102679","DOIUrl":"10.1016/j.rpth.2025.102679","url":null,"abstract":"<div><h3>Background</h3><div>Literature shows that atrial fibrillation (AF) patients with a history of cancer have a higher risk of thromboembolism (TE) and major bleeding (MB) compared to patients without. However, cancer type and time between cancer and AF diagnosis is often lacking in such analyses.</div></div><div><h3>Objectives</h3><div>To examine MB and TE rates of AF patients with a prior cancer diagnosis, stratified by cancer type and interval between cancer and AF diagnosis.</div></div><div><h3>Methods</h3><div>This Danish population-based cohort study included all patients aged ≥50 years with incident AF between January 1, 1995, and December 31, 2016, and identified those who had cancer before the AF diagnosis. From hospital and drug prescription databases, data on cancer type, time interval between cancer and AF diagnosis (ie, &lt;1, 1-3, or &gt;3 years), outcomes, and antithrombotic exposure were collected. Follow-up started from the AF diagnosis until the occurrence of an outcome or the end of the 2-year follow-up. Incidence rates (IRs) per 100 patient-years and adjusted hazard ratios (aHRs) with corresponding 95% CIs were calculated using Cox regression.</div></div><div><h3>Results</h3><div>We identified 39,178 patients with incident AF and a prior cancer diagnosis. These patients demonstrated higher MB (IR, 3.35 [3.25-3.45] vs 2.23 [2.29-2.35]) and TE rates (IR, 3.21 [3.11-3.31] vs 2.53 [2.50-2.56]) than those without prior cancer. The higher MB risk in AF patients with a prior cancer diagnosis was observed in all examined time intervals, while a higher TE risk was only observed in those with a cancer diagnosis &lt;1 year prior (aHR, 1.27 [1.16-1.40]). Prior respiratory cancer was associated with increased MB (aHR, 1.37 [1.26-1.48]) and TE risks (aHR, 1.26 [1.15-1.38]).</div></div><div><h3>Conclusion</h3><div>A prior cancer diagnosis confers additional MB and, to a lesser extent and in certain conditions, thromboembolic risks in patients with AF. The type and timing of the prior cancer diagnosis determines the degree of risk.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 2","pages":"Article 102679"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}